Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling

被引:411
作者
He, YL
Kozaki, KI
Karpanen, T
Koshikawa, K
Yla-Herttuala, S
Takahashi, T
Alitalo, K
机构
[1] Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland
[4] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 4648681, Japan
[5] Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland
关键词
D O I
10.1093/jnci/94.11.819
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Vascular endothelial growth factor C (VEGF-C) stimulates tumor lymphangiogenesis (i.e., formation of lymphatic vessels) and metastasis to regional lymph nodes by interacting with VEGF receptor 3 (VEGFR-3). We sought to determine whether inhibiting VEGFR-3 signaling, and thus tumor lymphangiogenesis, would inhibit tumor metastasis. Methods: We used the highly metastatic human lung cancer cell line NCI-H460-LNM35 (LNM35) and its parental line NCI-H460-N15 (N15) with low metastatic capacity. We inserted genes by transfection and established a stable N15 cell line secreting VEGF-C and a LNM35 cell line secreting the soluble fusion protein VEGF receptor 3-immunoglobulin (VEGFR-3-Ig, which binds VEGF-C and inhibits VEGFR-3 signaling). Control lines were transfected with mock vectors. Tumor cells were implanted subcutaneously into severe combined immunodeficient mice (n = 6 in each group), and tumors and metastases were examined 6 weeks later. In another approach, recombinant adenoviruses expressing VEGFR-3-Ig (AdR3-Ig) or P-galactosidase (AdLacZ) were injected intravenously into LNM35 tumor-bearing mice (n = 14 and 7, respectively). Results: LNM35 cells expressed higher levels of VEGF-C RNA and protein than did N15 cells. Xenograft mock vector-transfected LNM35 tumors showed more intratumoral lymphatic vessels (15.3 vessels per grid; 95% confidence interval [CI] = 13.3 to 17.4) and more metastases in draining lymph nodes (12 of 12) than VEGFR-3-Ig-transfected LNM35 tumors (4.1 vessels per grid; 95% CI = 3.4 to 4.7; P<.001, two-sided t test; and four lymph nodes with metastases of 12 lymph nodes examined). Lymph node metastasis was also inhibited in AdR3-Ig-treated mice (AdR3-Ig = 0 of 28 lymph nodes; AdLacZ = 11 of 14 lymph nodes). However, metastasis to the lungs occurred in all mice, suggesting that LNM35 cells can also spread via other mechanisms. N15 tumors overexpressing VEGF-C contained more lymphatic vessels than vector-transfected tumors but did not have increased metastatic ability. Conclusions: Lymph node metastasis appears to be regulated by additional factors besides VEGF-C. Inhibition of VEGFR-3 signaling can suppress tumor lymphangiogenesis and metastasis to regional lymph nodes but not to lungs.
引用
收藏
页码:819 / 825
页数:7
相关论文
共 38 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]   LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[3]   Vascular endothelial growth factor C induces angiogenesis in vivo [J].
Cao, YH ;
Linden, P ;
Farnebo, J ;
Cao, RH ;
Eriksson, A ;
Kumar, V ;
Qi, JH ;
Claesson-Welsh, L ;
Alitalo, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14389-14394
[4]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[5]  
deWaal RMW, 1997, AM J PATHOL, V150, P1951
[6]   Cardiovascular failure in mouse embryos deficient in VEGF receptor-3 [J].
Dumont, DJ ;
Jussila, L ;
Taipale, J ;
Lymboussaki, A ;
Mustonen, T ;
Pajusola, K ;
Breitman, M ;
Alitalo, K .
SCIENCE, 1998, 282 (5390) :946-949
[7]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[8]   Hyperplasia of lymphatic vessels in VEGF-C transgenic mice [J].
Jeltsch, M ;
Kaipainen, A ;
Joukov, V ;
Meng, XJ ;
Lakso, M ;
Rauvala, H ;
Swartz, M ;
Fukumura, D ;
Jain, RK ;
Alitalo, K .
SCIENCE, 1997, 276 (5317) :1423-1425
[9]   Proteolytic processing regulates receptor specificity and activity of VEGF-C [J].
Joukov, V ;
Sorsa, T ;
Kumar, V ;
Jeltsch, M ;
ClaessonWelsh, L ;
Cao, YH ;
Saksela, O ;
Kalkkinen, N ;
Alitalo, K .
EMBO JOURNAL, 1997, 16 (13) :3898-3911
[10]  
Joukov V, 1996, EMBO J, V15, P290